MENU CLOSE

Norwalk, Conn., December 7, 2023 – The Multiple Myeloma Research Foundation (MMRF) announced today that data from its landmark CoMMpass Study and Immune Atlas fueled 12 oral presentations to be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from December 9-12. In total, 34 different presentations use MMRF data. These advances represent important and continued innovation in multiple myeloma research.

“Our investment in the generation, analysis, and sharing of robust research and clinical data is fundamental to our relentless effort to drive progress in multiple myeloma treatment and ultimately a cure for each and every patient,” said Michael Andreini, President and CEO at the MMRF. “For over a decade, CoMMpass data has been analyzed by more than 300 researchers worldwide, making it one of the most highly published datasets in myeloma.”

Among the 34 CoMMpass abstracts to be highlighted at ASH are findings related to predictive biomarkers, disease progression, therapeutic resistance, risk assessment, genetic profiling to interpret the outcomes of early intervention for high-risk smoldering myeloma, and precision medicine.

One oral presentation from the Immune Atlas team reports on the results of single-cell RNA sequencing of bone marrow cell samples from 263 multiple myeloma patients enrolled at time of diagnosis in the CoMMpass Study. Using single cell transcriptomics, researchers captured the TIME (tumor immune microenvironment) and correlated specific immune cell populations and phenotypes with relapse risk and poor prognostic outcomes. These results suggest that immune subpopulations may be an essential novel aspect for improving current risk stratification models. These single-cell data are also part of a prognostic analysis of myeloma subtypes reported in a second oral presentation, in which collaborators at Genentech develop more refined subtypes using this Immune Atlas data, with improved characterization of early relapse.

“The Immune Atlas data have shown how immune function provides additional information beyond tumor subtyping, refining our understanding of risk and potentially advancing prognostication and strategies for clinical trials,” said George Mulligan, PhD, Chief Scientific Officer at the MMRF. “We will continue to push the envelope of innovative science in our urgent pursuit of better clinical strategies and more effective treatments for each and every patient with multiple myeloma.”

About the MMRF CoMMpassSM Study

The CoMMpass Study is an ongoing study of patients with active multiple myeloma, who enrolled at diagnosis and are being followed for eight years. The study maps patients’ tumor genomic profile to clinical outcomes with the goal of developing a more complete understanding of both disease biology and the patient’s response to treatments. With its inclusion in more than 300 published or presented studies, CoMMpass represents the largest longitudinal genomic dataset in multiple myeloma and has led to groundbreaking discoveries that have transformed how researchers understand the biology of the disease. The MMRF makes the CoMMpass data available to researchers globally and updates results at regular intervals.

About Immune Atlas

The MMRF Immune Atlas is a collaboration to study the immune system in multiple myeloma and establish a “gold standard” immune profiling platform for use in multiple myeloma research studies. This information, from hundreds of patients, will be combined with the existing genomic and clinical data from our CoMMpass Study to develop a more comprehensive picture of myeloma disease biology. These resulting insights will be helpful in guiding optimal therapy for myeloma patients.

About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.

###

Multiple Myeloma Research Foundation Media Contact:

C.J. Volpe
Director, PR and Communications
203-652-0453
[email protected]

Norwalk, Conn., November 30, 2023 — The Multiple Myeloma Research Foundation (MMRF) announced today the first recipients of its Scholars Program to improve equity in myeloma research and overall outcomes by increasing workforce diversity.  

Awardees Eden Biltibo, MD, MS, Assistant Professor at Vanderbilt University Medical Center, and Joselle Cook, MBBS, Assistant Professor at Mayo Clinic Rochester, will each be awarded up to $100,000 per year for four years to support their career development to first-tenure track positions. The Scholars Program is an annual initiative from the MMRF, with support from Pfizer and GSK, to provide grant funding for Black researchers and clinicians (MD and/or PhD) who are currently active or interested in pursuing a research and/or clinical career in the field of myeloma.  

“Multiple myeloma is a disease that disproportionately affects Black people and we are committed to ensuring that researchers and clinicians within the field more closely represent this patient population,” said Michael Andreini, President and CEO at the MMRF. “Dr. Biltibo and Dr. Cook’s work will add tremendous value to our field to advance understanding and treatment of myeloma across diverse patient communities.”

Black patients make up 20 percent of the approximately 35,000 people diagnosed with myeloma annually in the United States. Despite the high incidence of myeloma in the Black community, most Black patients are diagnosed later when compared to other patient populations, and increases in survival rates for Black patients have not kept pace with improved survival rates seen in other patient populations. Black patients are also underrepresented in the research and clinical studies that are driving new treatments, accounting for only 5 percent of clinical trial participants in the United States. In addition, Black researchers and clinicians are significantly underrepresented in hematology-oncology, comprising less than 4 percent of oncology fellows and only 3 percent of medical oncologists in the United States. Through initiatives like the Scholars Program, the MMRF is committed to improving diversity and inclusion in the research and clinical fields to drive health equity for all patient groups with myeloma. 

About the Research Scholar Awardee Grants 

Dr. Biltibo’s proposal entitled, “Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing,” focuses on equitable, utilization of immunotherapeutics in multiple myeloma and improving racial diversity of clinical trial participants in the same field. She will lead a single-arm phase II, non-inferiority clinical trial that will compare the 2-year MRD-negativity rate of subcutaneous 8-weekly DARZALEX® (daratumumab) and daily REVLIMID® (lenalidomide) maintenance therapy with 4-weekly DARZALEX® (daratumumab) and daily REVLIMID® (lenalidomide) maintenance therapy using a historical treatment cohort from the GRIFFIN trial.

Dr. Cook’s proposal entitled, “Prevalence of MGUS Among Unique Populations of Black People,” will determine the prevalence of monoclonal gammopathy of undetermined significance (MGUS), a precursor disease to multiple myeloma, among East African people in Minnesota and an Afro-Caribbean population in Trinidad.  She will lead a team that will use modern tools such as mass spectrometry to identify the presence of monoclonal protein. For those with positive MGUS tests, genome wide association studies and single nucleotide polymorphism (SNP) analysis will be performed to determine ancestral origins and correlate with the prevalence of SNPs known to be associated with higher prevalence of certain IgH translocations.

About Multiple Myeloma 

Multiple myeloma is the second most common blood cancer in the US. It develops in the bone marrow and can spread throughout the body. In 2023, multiple myeloma is expected to be diagnosed in more than 35,000 Americans and take the lives of 12,000. Despite advances, most patients relapse and there is still no cure. Multiple myeloma is twice as common in the Black community compared to other ethnicities and the outcomes for Black patients are generally worse than that of white patients.  

About the Multiple Myeloma Research Foundation  

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, use data to drive optimal and more personalized treatment approaches, and empower myeloma patients with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.

###

Multiple Myeloma Research Foundation Media Contact:

C.J. Volpe, Director, PR and Communications
203-652-0453
[email protected]

Norwalk, Conn., November 15, 2023 — The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Reverb Therapeutics to explore the potential of its antibody-based Amplifier™ platform for the treatment of multiple myeloma with endogenous cytokines that naturally occur within the body.

Reverb is a seed-stage oncology company with a highly differentiated platform approach to cytokine therapy. Its Amplifier™ platform uses antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines. Instead of using heavily engineered exogenous cytokines to treat diseases, which present challenges such as systemic toxicity and immunogenicity, Reverb’s antibodies redirect endogenous cytokines already in the body to cells of interest. With this round of funding, the MIF joins Reverb’s founding and lead investor Amplitude Ventures to support the company’s initial debut of its platform for the potential treatment of multiple myeloma and other cancers.

“We look forward to our partnership with Reverb Therapeutics and the potential of its Amplifier platform as a treatment for multiple myeloma,” said Michael Andreini, President and CEO at the Multiple Myeloma Research Foundation. “The MIF is committed to identifying and accelerating the most innovative treatment approaches for myeloma patients and we are excited by the potential of this novel approach to cytokine therapy.”

“We are excited about the power that the Myeloma Investment Fund brings to Reverb Therapeutics,” said David de Graaf, PhD, Founder and CEO of Reverb Therapeutics. “Having the scientific and clinical team at the MMRF available to an early-stage company is unique. We can translate their knowledge, focus, and dedication to improve the lives of multiple myeloma patients into impactful therapies such as our IL-15 programs.”

###

About the Myeloma Investment Fund

The Myeloma Investment Fund is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit www.myelomainvestmentfund.org

About the Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, use data to drive optimal and more personalized treatment approaches, and empower myeloma patients with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has raised over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.

About Reverb Therapeutics 

Based in Vancouver, Reverb Therapeutics is the leader in the development of treatments for cancer and other diseases using the body’s natural endogenous cytokines. Reverb’s Amplifier™ Antibody platform avoids the systemic toxicity normally associated with cytokine treatments by increasing cytokine levels only in targeted tissues. Elements of Amplifier antibodies are reusable, allowing Reverb to rapidly scale its pipeline across multiple disease areas. Learn more about opportunities to work with Reverb by contacting [email protected].

###

Multiple Myeloma Research Foundation Media Contact:

C.J. Volpe, Director, PR and Communications
203-652-0453
[email protected]

Norwalk, Conn., November 2, 2023 — The Multiple Myeloma Research Foundation® (MMRF®) announced today the recipients of three $7 million MMRF Myeloma Accelerator Challenge (MAC) Program Grants totaling $21 million. Each of these three-year multicenter translational projects aim to foster collaboration and advance compelling hypotheses that are ready for rapid testing in clinical trials, a critical step in the MMRF’s urgent pursuit of a cure for each and every myeloma patient.

“The MMRF makes significant strategic investments to generate robust molecular and clinical data and deliver translational research that drives better treatment options for patients,” said George Mulligan, PhD, Chief Scientific Officer at the MMRF. “These MAC Grants are a critical new part of this investment, and we are excited that the programs selected will bring together multiple centers to work in highly collaborative networks. Our strategic plan identifies specific research areas that need more attention and only through multi-center collaboration can we rapidly create a large set of patients and samples suitable for new research methods.”

The MAC Grants are focused on two critical areas of unmet need in myeloma and are part of the MMRF’s strategic priority to drive optimal treatment approaches for patients. The first is optimizing first-line therapy for high-risk newly diagnosed multiple myeloma because high-risk patients often relapse early and show inferior survival compared to standard-risk patients. The next is improving identification of high-risk smoldering multiple myeloma (HR SMM); smoldering multiple myeloma is an early, asymptomatic stage that can progress to active multiple myeloma. For each research topic, the pooling of resources and samples across a network of institutions dramatically improves the ability to drive meaningful results.

“The pace of research needs to accelerate if we are to address the significant unmet needs in multiple myeloma, and the way forward will take collaboration and funding,” said Michael Andreini, President and CEO at the MMRF. “Bringing together diverse teams through our MAC Grants that normally have many barriers to working together will bring greater focus and scale to these research priorities, yielding more timely and impactful insights for patients.”

 __

About the MAC Grant Networks

Clinical & Multi-Omics Platforms to Define High-Risk Smoldering Multiple Myeloma.

Sagar Lonial, MD, Winship Cancer Institute of Emory University, is leading a network of institutions including Atrium Health Levine Cancer Institute, Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Mayo Clinic, Memorial Sloan Kettering Cancer Institute, and Dana-Farber Cancer Institute. This team will develop an improved definition of high-risk SMM through the generation and analysis of new SMM patient data. These include use of cutting-edge technologies and a large, collaborative set of patient samples, with the goal of better defining which patients are suited for early intervention, which types of interventions can have the greatest impact, and which patients can safely be observed due to a low risk of disease progression.

A Systems Biology Approach to High-Risk Multiple Myeloma.

Prof. Pieter Sonneveld, MD, PhD, Erasmus Medical Center, is leading a European network of institutions including Erasmus Medical Center in Rotterdam, Amsterdam University Medical Centers, Julius Maximilian University of Würzburg, University of Turin, and the University of Salamanca. This team will investigate what makes less responsive, high-risk patients different from other patients with multiple myeloma. By combining different aspects of the disease, researchers will compile an integrated definition of high-risk multiple myeloma, a key step towards new treatments specifically designed for these patients.

 Transforming Treatment of High-Risk Myeloma.

Samir Parekh, MD, the Tisch Cancer Center at Mount Sinai, is leading a network of institutions including Albert Einstein Medical College, Hackensack University Medical Center, Stanford University Medical Center, University of California San Francisco, and Washington University of St. Louis. Using cutting-edge technologies, this team will analyze a large cohort of patient samples at the genomic and immune level to understand the critical events that drive high-risk multiple myeloma. The studies have the potential to identify new vulnerabilities that will be further studied using CRISPR gene editing in the laboratory.

About Multiple Myeloma

Multiple myeloma is the second most common blood cancer in the US. It develops in the bone marrow and can spread throughout the body. In 2023, multiple myeloma is expected to be diagnosed in more than 35,000 Americans and take the lives of 12,000. Despite advances, most patients relapse and there is still no cure. Multiple myeloma is twice as common in the Black community compared to other ethnicities and the outcomes for Black patients are generally worse than that of white patients.

About the Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, use data to drive optimal and more personalized treatment approaches, and empower myeloma patients with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has raised over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.

###

Multiple Myeloma Research Foundation Media Contact:

C.J. Volpe, Director, PR and Communications
203-652-0453
[email protected]

20-year industry veteran to lead development, execution of MIF investment strategy

Norwalk, Conn., Oct. 5, 2023 — The Multiple Myeloma Research Foundation® (MMRF®) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund® (MIF®). In this role, Dr. Oestreich will lead the overall execution of the MIF’s investment strategy and serve as a member of the MMRF executive leadership team.

“We are thrilled to have Dr. Oestreich join our team as Managing Director of the MIF,” said Michael Andreini, President and CEO, the MMRF. “The MIF invests in the most promising companies that are developing innovative clinical assets and technologies that could be transformative for myeloma patients. Dr. Oestreich brings a wealth of business development experience in biopharma and biotech that will play an invaluable role in the continued growth and impact of our fund.”

Dr. Oestreich has more than 20 years of diverse experience in business development and strategic alliances spanning large biopharma, biotech, and early academic research. Previously, she served as Chief Business Officer at the biotech Galecto and Vice President at the cell therapy company Mnemo Therapeutics. In addition, Dr. Oestreich was a Venture Partner at RA Capital and Executive Vice President at Evotec, where she built its North American investment arm and started an incubator with Samsara BioCapital. Her experience also includes work at F. Roche Hoffmann-La Roche Ltd., where she served as International Business Leader, and Novartis in Business Development and in Commercial. 

“The MMRF has made a tremendous impact to help advance new therapies for myeloma patients and I am truly excited to join this effort as Managing Director of the MIF,” said Dr. Oestreich. “Through the MIF’s investment strategy, we will continue our work to advance the development of novel treatments and innovative therapeutic strategies for patients.”

In addition to her role at the MIF, Dr. Oestreich currently serves on the boards of the German American Business Council in Boston and the Harvard Kennedy School’s Women’s Network and is the chair of the McCloy Alumni Association. She is also on the faculty of MIT, a member of the Launchpad Venture Group, an advisor at grIP Venture Studio to Biognosys (a Bruker company), Invitris, CART company CelineTx, and to the drug development and investment company Orange Grove Bio. She is also a member of the W20 Entrepreneurship task force, the official engagement group of the G20. 

To learn more about the MIF, visit www.myelomainvestmentfund.org.

###

About the Myeloma Investment Fund (MIF)

The Myeloma Investment Fund (MIF) is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit www.myelomainvestmentfund.org.

###

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.

###

Multiple Myeloma Research Foundation Media Contact:

C.J. Volpe, Director, PR and Communications
203-652-0453
[email protected]

Findings underscore the ongoing value to the myeloma scientific community of the MMRF’s landmark molecular and clinical data and translational research programs

Norwalk, CT, September 27, 2023 – The Multiple Myeloma Research Foundation (MMRF) today announced that findings from three studies based on analyses of its CoMMpass℠ and CureCloud℠ datasets will be featured in an oral abstract and poster presentations at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece, September 27-30, 2023. Topics include:

Additionally, data from the CoMMpass Study are cited in 24 posters and four education sessions, demonstrating its enduring value in driving new advancements across multiple myeloma research. With its inclusion in more than 300, CoMMpass represents the largest longitudinal genomic dataset in multiple myeloma and has led to groundbreaking discoveries that have transformed how researchers understand the biology of the disease.

To develop a more comprehensive picture of myeloma disease biology, the MMRF is expanding the CoMMpass dataset with immune data from its Immune Atlas research program. In addition, the MMRF’s CureCloud, a first-of-its-kind registry, has amassed clinical, genomic, immune, and patient-reported outcome (PRO) data across more than 1,000 participants. The MMRF makes the datasets from CoMMpass, Immune Atlas, and CureCloud available to researchers, facilitating the development of optimal treatments for all myeloma patients.

“Our consistent investment in the generation, analysis and sharing of new data with researchers worldwide accelerates the pace of scientific discovery to benefit each and every myeloma patient,” said George Mulligan, Ph.D., Chief Scientific Officer of the MMRF and co-author on two of the studies to be shared at IMS. “I am optimistic that, with greater understanding of this disease biology and continued collaboration in the research community, multiple myeloma patients will have improved therapeutic options now and also steadily increasing approaches to rational and potentially curative treatment strategies.”

About the MMRF data to be shared at IMS 2023

Friday, September 29, 2023
Poster Session 3, 1:15 PM – 2:15 PM EEST

Multi-omic analysis of multiple myeloma subtypes reveals epigenetic programs of high-risk disease

Identifying the biology of high-risk multiple myeloma is critical to improving outcomes. Current markers imperfectly predict high-risk disease and there are limited data that integrate genetic, epigenetic, and transcriptional information with outcomes. DNA methylation data was generated based on 415 samples from the MMRF CoMMpass study and identified distinct epigenetic programs of high-risk disease.

Friday, September 29, 2023
Poster Session 3, 1:15 PM – 2:15 PM EEST

Single-Cell Profiling Reveals Inflammaging-associated Dysregulations in Rapidly Progressing Multiple Myeloma Patients

Modern therapies for multiple myeloma rely on the immune system for their effectiveness and positive outcomes. Dysregulation in the immune compartment can promote disease progress and hamper the effectiveness of immune-based therapies. In this study for the characterization of bone marrow and its association with the kinetics of multiple myeloma, researchers performed Single Cell Profiling on bone marrow samples from the MMRF CoMMpass cohort.

Friday, September 29, 2023
Poster Session 3, 1:15 PM – 2:15 PM EEST

The MMRF CureCloud research study: a real-world longitudinal investigation of patient treatments and outcomes, including Patient Reported Outcome (PRO) surveys

CureCloud integrates molecular and real-world evidence data, including electronic health records (EHR) and PROs collected at six-month intervals. This poster is an analysis of the baseline PRO data. In general, patients were able to answer the PRO instruments electronically. The results indicate that younger and less socioeconomically advantaged patients experienced higher financial toxicity.

###

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.

###

Multiple Myeloma Research Foundation Media Contact:

C.J. Volpe, Director, PR and Communications
203-652-0453
[email protected]

Norwalk, CT, August 10, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Talvey™ (talquetamab-tgvs) for the treatment of patients with heavily pretreated multiple myeloma. In response to the announcement, the Multiple Myeloma Research Foundation (MMRF) has issued the following statement:

“Although options for the treatment of multiple myeloma have expanded significantly in recent years, the disease remains incurable, and therefore, patients are in need of new treatment options,” said Michael Andreini, President and Chief Executive Officer, Multiple Myeloma Research Foundation. “Today’s approval of talquetamab provides patients with a new treatment approach for relapsed or refractory disease that is a welcome addition to the myeloma community.”

According to Janssen’s announcement, Talvey™ (talquetamab-tgvs) is a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. To learn more about Talvey™, please visit the Standard Drug Therapies section on our website.

###

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.

Media Contact:

C.J. Volpe 
Multiple Myeloma Research Foundation 
[email protected]
203-652-0453

JERUSALEM, Israel & NORWALK, Connecticut – May 16, 2023Nectin Therapeutics, a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088, Nectin’s first-in-class lead immunotherapy drug candidate, for the treatment of multiple myeloma.

“We look forward to our partnership with Nectin Therapeutics to evaluate NTX1088 as a potential therapy for multiple myeloma,” said Michael Andreini, President and Chief Executive Officer of the Multiple Myeloma Research Foundation. “The MIF is committed to identifying and accelerating the most innovative treatment approaches for myeloma patients. We are pleased to support this first-in-class antibody targeting PVR based on the potential to overcome immune evasion and enhance the immune system’s response against myeloma.”

“We are delighted to join forces with the Myeloma Investment Fund, allowing us to collaborate and explore the potential of our lead candidate, NTX1088, in the treatment of multiple myeloma,” said Fabian Tenenbaum, Chief Executive Officer of Nectin. “NTX1088 is currently being studied in patients with advanced and metastatic solid tumors, and we look forward to working closely with the MIF to uncover the role that PVR blockade may serve in addressing the unmet needs of myeloma patients.”

Together with the MIF’s investment, Nectin has raised over $33M supported by investments from aMoon, Peregrine Ventures, Israel Biotech Fund, Cancer Focus Fund and Integra Holdings.

###

About Nectin Therapeutics

Nectin Therapeutics is a biotechnology company aiming to transform the lives of cancer patients by leveraging its unique insights into the nectin pathway to develop the next generation of immune oncology (IO) therapies. The company’s differentiated therapies have the potential to achieve new standards for efficacy and patient response across a number of difficult-to-treat cancers. Nectin’s technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates. It has a world-class scientific and management team with deep experience in oncology drug development and a successful track record in building biotechnology companies and developing innovative therapies. Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, Israel Biotech Fund, Cancer Focus Fund, Integra Holdings and the Myeloma Investment Fund.

About NTX1088

NTX1088 is a first-in-class monoclonal antibody directed against a key immune checkpoint, PVR, also known as CD155. NTX1088 has multiple mechanisms of action. NTX1088 blocks the interaction between PVR and DNAM1, also known as CD226, a molecule involved in the activation of anti-cancer T and NK cells. By preventing internalization and degradation of DNAM1, NTX1088 leads to restoration of DNAM1 expression on the surface of immune cells and results in robust antitumor activity. NTX1088 also blocks PVR’s interactions with TIGIT and CD96, preventing their immune inhibitory signaling. NTX1088 demonstrated superior antitumor activity compared to approved and investigational immune checkpoint inhibitors in preclinical models and had a favorable safety profile in non-human primates.

About the Myeloma Investment Fund (MIF)
The Myeloma Investment Fund (MIF) is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit www.myelomainvestmentfund.org.

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.

Media Contacts:

C.J. Volpe 
Multiple Myeloma Research Foundation 
[email protected]
203-652-0453

Rebecca Ash 
Gova10 for Nectin Therapeutics 
[email protected]
+972-52-663-5075

Norwalk, Conn., and San Francisco, Calif, Feb. 27, 2023 – The Multiple Myeloma Research Foundation (MMRF) and the Lazarex Cancer Foundation, a non-profit organization focused on  improving patient access to cancer clinical trials, announced today a partnership to support more equitable access to clinical trials for multiple myeloma cancer patients. This is the initial step of an action plan the MMRF developed to improve diversity and representation in myeloma clinical trials following its first Health Equity Summit focused on improving equity and inclusiveness in multiple myeloma clinical research.

“We at the MMRF believe that every myeloma patient should have an equal opportunity to participate in clinical trials and are deeply committed to improving representation in clinical research,”  said Michael Andreini, President and CEO at the MMRF. “We are pleased to partner with the Lazarex Cancer Foundation to improve the opportunities patients have to help advance development of new therapies and potentially benefit from emerging treatment approaches.”

As part of the partnership, the MMRF contributed $100,000 to Lazarex’s PATH Program, a service designed to improve enrollment and diversity in clinical trials through patient reimbursement of out-of-pocket travel costs, community outreach, and engagement. Lazarex will support patients in MMRF-funded clinical trials, as well as help multiple myeloma patients find information and enroll in open trials, as appropriate, through the Lazarex CARE program.

Multiple myeloma is a type of blood cancer that develops in the bone marrow and can spread throughout the body. It is expected to be diagnosed in 35,000 Americans in 2023 and take the lives of 12,000. Despite advances, most patients relapse and there is still no cure. Multiple myeloma is twice as common in the Black community compared to other ethnicities and is twice as deadly in Black patients compared to white patients. 

“Lazarex Cancer Foundation is honored to work alongside the MMRF to support patients with multiple myeloma with travel reimbursement and help them get to clinical trial treatments,” said Stephanie Rivera, MPH, CEO at Lazarex Cancer Foundation. “The MMRF is one of the few research organizations that clearly understands how we partner with research for successful completion of and improved diversity in cancer clinical trials. I see this as just the start of greater things to come for both organizations to benefit patients with multiple myeloma.”

Other elements of the MMRF’s partnership with the Lazarex Cancer Foundation include developing and expanding collateral, creating content for a speaker series on myeloma and supplying MMRF resources, such as the Patient Toolkit, to Lazarex Cancer Foundation activities.

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the  development and delivery of next-generation therapies, use data to drive optimal and more personalized treatment approaches, and empower myeloma patients with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.

About Lazarex Cancer Foundation
At Lazarex Cancer Foundation we strive to improve cancer health outcomes, FDA cancer clinical trial diversity, retention, and enrollment, and patient access to care by providing assistance with  clinical trial navigation, reimbursing trial related travel costs, and partnering with at-risk communities to mobilize resources. In 17 years Lazarex has assisted nearly 8,000 patients. Learn more at  www.Lazarex.org. Follow us @LazarexCF.

###

Multiple Myeloma Research Foundation Media Contact:
C.J. Volpe
Director, PR and Communications
Multiple Myeloma Research Foundation (MMRF)
203.652.0453
[email protected]

Norwalk, CT, Dec. 21, 2022 – The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced investments in Luminary Therapeutics, a company using advanced receptor design to improve the depth and durability of patient responses to cell therapy; KAHR, a clinical stage company developing immune-recruiting therapies to address immune escape by tumors; and Telo Therapeutics, a biotechnology company developing second generation inhibitors of nuclear transport against a clinically validated target for multiple myeloma.

These investments mark a significant expansion of the MIF portfolio, bringing the total number of active portfolio companies to nine and the total number of MIF investments to eleven. With these additions, the MIF continues to diversify its range of investments, consistent with its strategic approach to venture philanthropy to accelerate the most promising therapeutic advances for patients with multiple myeloma.

“We are extremely proud to partner with Luminary Therapeutics, KAHR, and Telo Therapeutics, three innovative companies furthering the development of new therapies that have the potential to improve the lives of multiple myeloma patients,” said Peter Kosa, Ph.D., Managing Director of the Myeloma Investment Fund. “By investing in three companies dedicated to developing novel therapies across a variety of innovative new targets and technologies, the MIF remains committed to advancing new treatment options to address unmet needs for multiple myeloma patients.”

The MIF’s investment in Luminary Therapeutics supports the development of Luminary’s BAFF-CAR-T, a first-of-its-kind CAR-T cell therapy that targets three distinct antigens present on multiple myeloma tumors. The MIF’s investment in KAHR supports continued development of DSP107, a dual-targeting fusion protein that activates innate and adaptive immunity by blocking CD47 on cancer cells and utilizing 4-1BB conditional co-stimulatory activation of T-cells. The MIF’s investment in Telo helps advance the company’s next generation nuclear transport inhibitors toward the clinic.

“The three investments in Luminary Therapeutics, KAHR, and Telo Therapeutics are consistent with our mission of accelerating potential life-extending therapies for multiple myeloma patients,” said Michael Andreini, President and CEO of the Multiple Myeloma Research Foundation. “By funding and partnering with innovative companies, we are continuing to advocate for novel technology platforms to be evaluated in the myeloma space where there is still great unmet need.”

For more information, visit myelomainvestmentfund.org, luminarytx.com, kahrbio.com, and telotherapeutics.com.

About the Multiple Myeloma Research Foundation (MMRF)

A pioneer in personalized medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of personalized treatments for cancer. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c)(3) nonprofit organization, the MMRF has created the benchmark business model around cancer—from data to analytics to the clinic. The MMRF identifies barriers and then finds the solutions to overcome them, bringing in the best partners and aligning incentives in the industry to drive better outcomes for patients. Since its inception, the organization has collected thousands of samples and tissues, opened nearly 100 trials, helped bring more than 15 FDA-approved therapies to market, and built CoMMpass, the single largest genomic dataset in myeloma. Today, the MMRF is building on its legacy in genomics and is expanding into immunotherapy, as the combination of these two fields will be critical to making personalized medicine possible for all patients. The MMRF has raised more than $500 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.

About the Myeloma Investment Fund

The Myeloma Investment Fund (MIF) is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits are reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit MyelomaInvestmentFund.org.

About KAHR

KAHR develops novel dual-targeting fusion protein therapeutics engineered to activate both the innate and the adaptive immune systems simultaneously and localize that response in the tumor microenvironment. KAHR’s lead product candidate, DSP107, is a CD47x41BB targeting compound. DSP107 is being tested in a Phase I/II clinical trial in advanced solid tumors and a Phase Ib clinical trial in blood cancers. KAHR’s preclinical pipeline includes DSP502, a PVRxPD-L1 targeting fusion protein, and DSP216, an HLA-GxCD47 targeting fusion protein. For more information, please visit https://kahrbio.com.

About Luminary Therapeutics

Luminary is a clinical stage allogeneic cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Luminary was founded by the team from B-MoGen that achieved a successful 5X exit in only three years. Luminary is seeking Series A financing with venture firms or strategic partners to support its first clinical trial and development of its disruptive Universal Receptor that can modulate antigen specificity. For more information visit www.luminarytx.com.

About Telo Therapeutics

Telo Therapeutics is developing orally bioavailable next generation inhibitors of nuclear transport, a critical nexus among many cancer cell signaling pathways. The company’s unique chemistry and distinct mechanism of action result in a favorable safety profile and lead to rapid tumor regressions across multiple cancer types including multiple myeloma, brain, liver, lung, bladder, and prostate. Telo has generated durable complete responses with just two weeks of dosing in xenografts of both multiple myeloma and glioblastoma. Telo is uniquely positioned to unlock the full potential of targeting nuclear transport in multiple myeloma tumors and beyond. Telo is actively raising a Series A financing to advance its small molecule to Investigational New Drug (IND) and run a Phase 1 proof-of-concept trial. Telo is targeting first patient dosing in 2H of 2024.

###

Multiple Myeloma Research Foundation Media Contact:

C.J. Volpe
Director, PR and Communications
Multiple Myeloma Research Foundation (MMRF)
203.652.0453
[email protected]